Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Franssen

Showing results (141-150 of 146) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 146 results.
Clinical Pharmacokinetics|July 25, 2025
TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic EvaluationFenna de Vries, Eric J F Franssen, Arthur A J Smit, et al.
Cancer Treatment and Research Communications|May 29, 2026
Early-onset hematological toxicity of docetaxel and survival in non-small cell lung cancer patients in the immune checkpoint inhibition eraM P Kicken, A J Grotenhuis, S de Kok, et al.
Clinical Lung Cancer|April 22, 2025
The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort StudyMart P Kicken, Rob Ter Heine, Intissar Azarfane, et al.
Targeted Oncology|April 20, 2023
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung CancerRob Ter Heine, Michel M van den Heuvel, Berber Piet, et al.
British Journal of Clinical Pharmacology|August 11, 2023
Adverse drug events caused by three high-risk drug-drug interactions in patients admitted to intensive care units: A multicentre retrospective observational studyJoanna E Klopotowska, Jan-Hendrik Leopold, Tinka Bakker, et al.
Journal of Critical Care|December 22, 2020
Clinically relevant potential drug-drug interactions in intensive care patients: A large retrospective observational multicenter studyTinka Bakker, Ameen Abu-Hanna, Dave A Dongelmans, et al.
Pageof 15

Showing results (141-150 of 146) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 146 results.
Clinical Pharmacokinetics|July 25, 2025
TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic EvaluationFenna de Vries, Eric J F Franssen, Arthur A J Smit, et al.
Cancer Treatment and Research Communications|May 29, 2026
Early-onset hematological toxicity of docetaxel and survival in non-small cell lung cancer patients in the immune checkpoint inhibition eraM P Kicken, A J Grotenhuis, S de Kok, et al.
Clinical Lung Cancer|April 22, 2025
The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort StudyMart P Kicken, Rob Ter Heine, Intissar Azarfane, et al.
Targeted Oncology|April 20, 2023
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung CancerRob Ter Heine, Michel M van den Heuvel, Berber Piet, et al.
British Journal of Clinical Pharmacology|August 11, 2023
Adverse drug events caused by three high-risk drug-drug interactions in patients admitted to intensive care units: A multicentre retrospective observational studyJoanna E Klopotowska, Jan-Hendrik Leopold, Tinka Bakker, et al.
Journal of Critical Care|December 22, 2020
Clinically relevant potential drug-drug interactions in intensive care patients: A large retrospective observational multicenter studyTinka Bakker, Ameen Abu-Hanna, Dave A Dongelmans, et al.
Pageof 15